Is NextCure, Inc. (NXTC) a Buy, Sell, or Hold?
NextCure, Inc.
NASDAQ:NXTC
$6.58 USD
$4.4 (201.83%)
- Volume
- 113.09M
- Average Volume
- 100.41K
- Market Capitalization
- $17.63M
- P/E Ratio
- -0.35
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $15.74
- Year Low
- $1.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.61
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael S. Richman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NXTC |
| CUSIP | 65343E207 |
| CIK | 0001661059 |
| Web | https://www.nextcure.com |
| Phone | 240-399-4900 |
| Currency | USD |
| Employees | 40 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.18 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.61 |
| Quick Ratio | 4.61 |
| Cash Ratio | 2.20 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -9.54 |
| Price / Cash Flow | -0.35 |
| Price / Book | 1.29 |
Price Target and Rating
| Average Stock Price Forecast | $15.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -56.13% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-19.65 |
| Trailing P/E Ratio | -0.35 |
| PEG Ratio | -0.12 |
| P/E Growth | -0.12 |
| Net Income | $-55.84M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -186.96% |
| Return on Assets | -143.94% |
Financials Score
| AltmanZ Score | -20.09 |
| Piotroski Score | 1.00 |
| Working Capital | 24.85M |
| Total Assets | 37.98M |
| Ebit | -54.66M |
| Market Cap | 5.84M |
| Total Liabilities | 11.26M |
Poll Results
About NextCure, Inc. (NASDAQ:NXTC) Stock
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing p ... reclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
2026-07-14 14:09:03
NextCure Inc. (NASDAQ:NXTC) on Tuesday agreed to merge with privately held biotechnology company Avere Therapeutics in an all-stock transaction that will take Avere public while providing $320 million in financing to advance its lead oral IL-23 therapy, AVR-001.
2026-07-14 14:00:00
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) PR Newswire
2026-07-14 13:34:00
NEW YORK, July 14, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating NextCure, Inc. (NASDAQ: NXTC ) related to its merger with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.
2026-07-14 12:00:00
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire
2026-07-14 11:41:00
MILWAUKEE, July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avere Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
2026-07-14 11:00:00
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. Upon closing of the pr
2026-07-14 10:59:00
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.Halper Sadeh encourages NextCure shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or.
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
2026-07-14 06:00:00
Avere Therapeutics' lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy
Frequently Asked Questions
-
What is the current NextCure, Inc. (NXTC) stock price?
-
NextCure, Inc.(NASDAQ:NXTC) stock price is $6.58 in the last trading session. During the trading session, NXTC stock reached the peak price of $15.74 while $1.55 was the lowest point it dropped to. The percentage change in NXTC stock occurred in the recent session was 201.83% while the dollar amount for the price change in NXTC stock was $4.4.
-
NXTC's industry and sector of operation?
-
The NASDAQ listed NXTC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NXTC?
-
Sourav Kundu | Senior Vice President of Development & Manufacturing
Kevin G. Shaw | Senior Vice President & General Counsel
Steven Cobourn | Chief Financial Officer
Lieping Chen | Co-Founder & Chairman of Scientific Advisory Board
Sebastien Maloveste | Senior Vice President of Business Development -
How many employees does NXTC have?
-
Number of NXTC employees currently stands at 40. NXTC operates from 9000 Virginia Manor Road, Beltsville, MD 20705, US.
-
Link for NXTC official website?
-
Official Website of NXTC is: https://www.nextcure.com
-
How do I contact NXTC?
-
NXTC could be contacted at phone #240-399-4900 and can also be accessed through its website. NXTC operates from 9000 Virginia Manor Road, Beltsville, MD 20705, US.
-
How many shares of NXTC are traded daily?
-
The average number of NXTC shares traded daily for last 3 months was 100.41K.
-
What is the market cap of NXTC currently?
-
The market value of NXTC currently stands at $17.63M with its latest stock price at $6.58